Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000300020 refers to a transcript annotated as being antisense to the protein-coding gene CFAP61. Unlike CFAP61, which encodes a component of the calmodulin- and spoke-associated complex crucial for sperm flagellum structure and function[1][2], this antisense transcript does not code for a known protein and has no established biological or therapeutic relevance. It is not recognized as a therapeutic target, nor is there evidence linking it to drug interactions, disease mechanisms, or biomarker utility. Its functional significance remains uncharacterized, and no literature supports a direct role in human disease or physiology. The entry likely reflects an uncharacterized or predicted non-coding transcript in the genomic vicinity of CFAP61, rather than a distinct, validated target suitable for therapeutic intervention[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to CFAP61.